title: Correlation of surrogate markers of Gaucher disease. Implications for long-term follow up of enzyme replacement therapy.
abstract: BACKGROUND
  The excessive storage of cellular debris in the lysosomal storage disorders triggers a variety of cellular responses. Some of these responses are maladaptative and result in the pathology of these diseases. To some extent, cellular responses are specific to the stored material, which influences the pathophysiology of the disease and results in some of its characteristic features.
  
  
  METHODS
  A large body of data has been collected for three biochemical (surrogate) markers of Gaucher Disease: angiotensin converting enzyme (ACE), tartrate-resistant acid phosphatase (TRAP) and chitotriosidase (CHITO) using currently available enzyme analysis. Follow up data was gathered in a group of 18 patients.
  
  
  RESULTS
  The three markers are correlated between each other and are useful indicators of the disease progress and its response to enzyme replacement therapy (ERT). Retrospective analysis of clinical records and comparison of chitotriosidase values with the baseline Severity Score Index (SSI) allowed prediction of the response patterns for this marker when long-term ERT (>24 months) was evaluated.
  
  
  CONCLUSIONS
  The less severely affected patients are more likely to normalize their chitotriosidase activities after long term ERT.
authors.affiliation: Department of Human Genetics, University of Pittsburgh, E1650, Biomedical Science Tower, Pittsburgh, PA, 15261, USA.
authors.forename: Mario A
authors.initials: MA
authors.lastname: Cabrera-Salazar
authors.forename: Erin
authors.initials: E
authors.lastname: O'Rourke
authors.forename: Nadene
authors.initials: N
authors.lastname: Henderson
authors.forename: Howard
authors.initials: H
authors.lastname: Wessel
authors.forename: John A
authors.initials: JA
authors.lastname: Barranger
mesh_terms: D000135:Acid Phosphatase / Q000032:analysis; D015415:Biomarkers / Q000032:analysis; D018450:Disease Progression; D016903:Drug Monitoring / Q000379:methods*; D057487:Enzyme Therapy; D004798:Enzymes / Q000032:analysis*; D005500:Follow-Up Studies; D005776:Gaucher Disease / Q000175:diagnosis* / Q000188:drug therapy*; D006596:Hexosaminidases / Q000032:analysis; D006801:Humans; D007527:Isoenzymes / Q000032:analysis; D007703:Peptidyl-Dipeptidase A / Q000032:analysis; D012189:Retrospective Studies; D012720:Severity of Illness Index; D000071681:Tartrate-Resistant Acid Phosphatase
chemical_list: D015415:Biomarkers; D004798:Enzymes; D007527:Isoenzymes; D000135:Acid Phosphatase; D000071681:Tartrate-Resistant Acid Phosphatase; D006596:Hexosaminidases; C086400:chitotriosidase; D007703:Peptidyl-Dipeptidase A